Related Experiment Video
Updated: Mar 6, 2026
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family
Kristine K Deibler1, Rama K Mishra2, Matthew R Clutter3
1Department of Chemistry, Northwestern University , Evanston, 60208, Illinois, United States.
Abstract:
MEK4 is an upstream kinase in MAPK signaling pathways where it phosphorylates p38 MAPK and JNK in response to mitogenic and cellular stress queues. MEK4 is overexpressed and induces metastasis in advanced prostate cancer lesions. However, the value of MEK4 as an oncology target has not been pharmacologically validated because selective chemical probes targeting MEK4 have not been developed. Despite a high level of sequence homology in the ATP-binding site, most reported MEK inhibitors are selective for MEK1/2 and display reduced potency toward other MEKs. Here, we present the first functional and binding selectivity-profiling platform of the MEK family. We applied the platform to profile a set of known kinase inhibitors and used the results to develop an in silico approach for small molecule docking against MEK proteins. The docking studies identified molecular features of the ligands and corresponding amino acids in MEK proteins responsible for high affinity binding versus those driving selectivity. WaterLOGSY and saturation transfer difference (STD) NMR spectroscopy techniques were utilized to understand the binding modes of active compounds. Further minor synthetic manipulations provide a proof of concept by showing how information gained through this platform can be utilized to perturb selectivity across the MEK family. This inhibitor-based approach pinpoints key features governing MEK family selectivity and clarifies empirical selectivity profiles for a set of kinase inhibitors. Going forward, the platform provides a rationale for facilitating the development of MEK-selective inhibitors, particularly MEK4 selective inhibitors, and repurposing of kinase inhibitors for probing the structural selectivity of isoforms.
Insights
Developing selective MEK4 inhibitors is crucial for cancer therapy. This study introduces a novel platform to profile MEK family kinases, enabling the design of targeted inhibitors for advanced prostate cancer and other diseases.
Area of Science:
- Biochemistry and Molecular Biology
- Pharmacology
- Medicinal Chemistry
Background:
- Mitogen-activated protein kinase kinase 4 (MEK4) is a key kinase in MAPK signaling pathways, implicated in cellular stress responses and cancer progression.
- Overexpression of MEK4 correlates with metastasis in advanced prostate cancer, highlighting its potential as an oncology target.
- Existing MEK inhibitors primarily target MEK1/2, lacking selectivity for MEK4 due to conserved ATP-binding sites.
Purpose of the Study:
- To develop and validate a functional and binding selectivity-profiling platform for the MEK kinase family.
- To identify molecular features governing MEK family selectivity using computational and experimental approaches.
- To provide a foundation for developing MEK4-selective inhibitors and repurposing existing kinase inhibitors.
Main Methods:
- Established a comprehensive platform for functional and binding selectivity profiling of MEK family kinases.
- Employed in silico small molecule docking against MEK proteins, informed by profiling data.
- Utilized Water-transfer ligand observed, via saturation transfer difference (WaterLOGSY) and saturation transfer difference (STD) Nuclear Magnetic Resonance (NMR) spectroscopy to elucidate compound binding modes.
Main Results:
- The developed platform successfully profiled known kinase inhibitors against the MEK family.
- In silico docking identified key molecular interactions responsible for MEK protein binding affinity and selectivity.
- NMR studies provided detailed insights into the binding mechanisms of active compounds.
- Demonstrated proof-of-concept for manipulating selectivity through minor synthetic modifications.
Conclusions:
- The study presents the first functional and binding selectivity-profiling platform for the MEK family.
- This platform facilitates the rational design of selective MEK inhibitors, particularly for MEK4.
- The findings aid in understanding kinase inhibitor selectivity and offer strategies for drug repurposing.
